Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours

BACKGROUND: The epidermal growth factor receptor-targeted monoclonal antibody cetuximab (Erbitux) was recently introduced for the treatment of metastatic colorectal cancer. Treatment response is dependent on Kirsten-Ras (K-Ras) mutation status, in which the majority of patients with tumour-specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Weidlich, S, Walsh, K, Crowther, D, Burczynski, M E, Feuerstein, G, Carey, F A, Steele, R J C, Wolf, C R, Miele, G, Smith, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142798/
https://www.ncbi.nlm.nih.gov/pubmed/21712828
http://dx.doi.org/10.1038/bjc.2011.197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142798/
https://www.ncbi.nlm.nih.gov/pubmed/21712828
http://dx.doi.org/10.1038/bjc.2011.197

Ejemplares similares